Biotech company
Appears in 1 story
Filing for FDA approval of miv-cel in stiff person syndrome
Novartis paused its autoimmune CAR-T trials this month after three patients died from a severe immune reaction, and Bristol Myers paused its own over similar inflammatory events. The same week, Kyverna Therapeutics released 12 months of follow-up data on miv-cel, its rival therapy, reporting sustained improvement in stiff person syndrome patients with no high-grade immune toxicity.
Updated 2 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
